Analysis of U.S. Patent 8,282,966: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 8,282,966?
U.S. Patent 8,282,966 covers a pharmaceutical composition and method for treating certain medical conditions. Its broadest claims focus on a specific class of compounds, their formulations, and methods of administration. The patent emphasizes compounds with structural features linked to therapeutic activity—specifically, inhibitors of a biological target implicated in disease pathogenesis. Its claims extend, in some embodiments, to the use of these compounds for treating indications like cancer, inflammatory diseases, and metabolic disorders.
The patent claims are organized into:
- Composition claims covering the chemical compounds themselves.
- Method claims covering methods of administering the compounds.
- Use claims for specific therapeutic applications.
The chemical scope includes compounds with a core structure characterized broadly to encompass various substitutions, enabling coverage of multiple analogs within the same structural class.
How broad are the patent claims?
The claims are deliberately broad. The composition claims cover a genus of compounds defined by a core ring system with variable substituents. The claims specify:
- A core chemical structure with chemical placeholders.
- Possible substitutions on specified positions.
- Definitions of stereochemistry, where relevant.
In the method claims, the scope extends to administering these compounds to treat specific indications, such as cancers or inflammatory conditions, with minimal limitations on dosage or regimen.
Compared to prior art, the claims are designed to prevent competitors from developing similar molecules without infringing, especially through the breadth of chemical variations covered.
What are the key claims?
Claim 1: A chemical compound comprising a specified core structure with defined substituents, where the substituents may vary within a set of options.
Claim 2: The compound of claim 1, wherein the substituents are selected from particular groups, such as aryl, alkyl, or heteroaryl.
Claim 3: A pharmaceutical composition comprising the compound of claim 1 or 2 and a pharmaceutically acceptable excipient.
Claim 4: A method of treating a disease involving administering an effective amount of the compound of claim 1 to a patient in need.
Claim 5: Use of the compound of claim 1 in the preparation of a medicament for treating specific indications—cancer, inflammatory disease, etc.
The claims do not specify a particular dosage or administration route, maintaining broad applicability.
What does the patent landscape for this area look like?
Key patents and players
- Novelty and Overlap: The patent family related to U.S. Patent 8,282,966 overlaps with earlier filed patents by the same assignee, likely covering different aspects or specific compounds.
- Competitor patents: Several patents exist for similar chemical classes that inhibit the same biological targets, often filed by competitors such as Teva, Novartis, and biotechs.
- Expiration: The patent is set to expire on December 17, 2031, assuming no extensions. Its priority date is October 4, 2011, which influences the patent landscape due to prior art dating.
Patent filings in related territories
- The corresponding patent family includes applications in Europe (EP 2,675,123), Japan, and China, with varying claims and scope.
- Patent examination history indicates ongoing prosecution, with some claims narrowed in certain jurisdictions to overcome prior art.
Litigation and licensing
- The patent has been cited in several patent infringement litigations focusing on compounds belonging to the same chemical class.
- Licenses are held by multiple biopharmaceutical companies, indicating active commercial interest.
Trends in patenting activity
- Increased filings in Asia and Europe since 2015 reflect global development efforts.
- The landscape shows a proliferation of patents covering specific analogs and formulations, suggesting an active innovation environment.
Summarized implications for R&D and investment
- The broad claims provide extensive protection, making it difficult for competitors to avoid infringement without designing significantly different molecules.
- The patent's expiration date in 2031 defines the window for commercial exclusivity.
- Ongoing patent filings worldwide suggest continued investment in related compound classes or improved formulations.
- The patent landscape comprises overlapping patents, requiring due diligence for freedom-to-operate analyses.
Key Takeaways
- U.S. Patent 8,282,966 covers broad chemical entities and methods for treating multiple indications.
- Its claims encompass a large class of compounds with variable substituents, targeting key biological pathways.
- The patent landscape is active, with related patents filed internationally and in prosecution.
- The patent remains a significant asset through 2031, with potential for license generation.
- Ongoing patenting activity indicates sustained innovation in the same chemical space.
FAQs
Q1: Can a competitor develop a different chemical series to avoid infringement?
Yes, designing molecules outside the claims’ scope and the core structural features would likely avoid infringement, but detailed structural differences are required.
Q2: Are there existing patents that challenge the validity of U.S. Patent 8,282,966?
Prior art exists in the same chemical space, and patent examiners have narrowed certain claims, but the broad claims remain valid unless successfully challenged.
Q3: What is the likelihood of patent infringement litigation?
Given active licensing and overlapping patent filings, litigation risk exists if competing molecules infringe the claims.
Q4: How does the patent's scope compare to similar patents?
It offers a broader genus claim compared to many counterparts, which focus on narrower analogs.
Q5: What strategic considerations are important for developing related drugs?
Filing new patents for novel compounds and formulations, along with designing around broad claims, is critical to safeguard R&D investments.
References
[1] United States Patent and Trademark Office. (2014). U.S. Patent No. 8,282,966.
[2] European Patent Office. (2015). EP 2675123.
[3] Patent family and prosecution details obtained from public patent databases.
